VivoSeq
Other

Moderate to Severe Postoperative Pain

0

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Moderate to Severe Postoperative Pain is an early-stage landscape with 0 programs across 1 company. The most active players are Johnson & Johnson.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

3

clinical trials

Completed3 · 100%

Clinical Trials

Trial Activity

A Study Comparing the Effectiveness and Safety of Extended Release (ER) Tramadol Hydrochloride (HCl)/Acetaminophen With Immediate Release (IR) Tramadol HCl/Acetaminophen in Participants With Moderate to Severe Postoperative Pain
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT01814878·320 enrolled
The Effect of Chlorzoxazone on Moderate to Severe Postoperative Pain After Spine Surgery
Completed·—·Phase 4·NCT01933542·110 enrolled
A Randomized, Open-Label, Single-Dose, Small Study to Evaluate the Safety and Effectiveness of Hydromorphone in Patients With Short Term, Moderate to Severe Postoperative Pain
Completed·AAlza Corporation, DE, USA·Phase 2·NCT00411307·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)